Table 3.
Strategies |
---|
Patient therapy preferences (setting, duration, etc.) |
Patient-centric measures of adequate KRT |
Biomarkers of adequate KRT |
Amount of KRT needed to minimize uremic symptoms and consequences |
Adequate animal uremic models that model human ESKD to test new products for safety and efficacy |
Identification of critical kidney functions that must be replaced and which ones can be treated with drugs or managed in other ways |
Taken with minor modifications from the Roadmap (Supplemental Appendix 1). KRT, kidney replacement therapy.